Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.

Richmond Laboratories carried out a phase I clinical trial Zutrab evaluating the pharmacokinetic and safety profile of Zutrab compared to Avastin and Cizumab (a ‘similar biologic’), to establish similarity.

Richmond Laboratories says that Zutrab is the first similar biological medicine from the company’s oncology line and is the result of a biotechnology project that began several years ago. In its communication with the National Securities Commission, the company said that, in the medium term, this project will include the launch of new biotechnological products, with clinical studies being carried out in the country. In addition, the company added that it expects to continue its expansion in this area.

Zutrab is a similar biological medicine of Roche’s Avastin (bevacizumab), which also has a presence in the Argentinian market. There are two other bevacizumab similar biological medicines approved in Argentina, Bevax and Lumiere, which are both produced by Elea Laboratory (Laboratorio Elea) [1].

Editor’s comment
European Medicines Agency regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product but they are not universally accepted by regulatory bodies outside of the European Union (EU). It should be noted that ‘similar biological medicines’ approved in Argentina and ‘similar biologics’ approved in India might not have been authorized if they had been subjected to the strict regulatory processes required for approval of biosimilars in the EU.

Related article
Argentinian guidelines for similar biological medicines

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Similar biotherapeutic products approved and marketed in Latin America [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 26]. Available from: www.gabionline.net/Biosimilars/General/Similar-biotherapeutic-products-approved-and-marketed-in-Latin-America

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.